MX388264B - Suministro mejorado de particulas virales al cuerpo estriado y al cortex. - Google Patents

Suministro mejorado de particulas virales al cuerpo estriado y al cortex.

Info

Publication number
MX388264B
MX388264B MX2017010370A MX2017010370A MX388264B MX 388264 B MX388264 B MX 388264B MX 2017010370 A MX2017010370 A MX 2017010370A MX 2017010370 A MX2017010370 A MX 2017010370A MX 388264 B MX388264 B MX 388264B
Authority
MX
Mexico
Prior art keywords
cortex
striatal
corporation
viral particles
enhanced delivery
Prior art date
Application number
MX2017010370A
Other languages
English (en)
Other versions
MX2017010370A (es
Inventor
Lamya Shihabuddin
Lisa M Stanek
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2017010370A publication Critical patent/MX2017010370A/es
Publication of MX388264B publication Critical patent/MX388264B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevos métodos para suministrar partículas virales adeno-asociadas recombinantes (rAAV) al sistema nervioso central de un mamífero (p. ej. un ser humano). En aspectos, los métodos comprenden administrar partículas de rAAV que contienen un ácido nucleico heterólogo al cuerpo estriado y causar la expresión del ácido nucleico heterólogo al menos en el córtex cerebral y en el cuerpo estriado del mamífero.
MX2017010370A 2015-02-10 2016-02-09 Suministro mejorado de particulas virales al cuerpo estriado y al cortex. MX388264B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562114544P 2015-02-10 2015-02-10
US201562220997P 2015-09-19 2015-09-19
PCT/US2016/017210 WO2016130591A2 (en) 2015-02-10 2016-02-09 Enhanced delivery of viral particles to the striatum and cortex

Publications (2)

Publication Number Publication Date
MX2017010370A MX2017010370A (es) 2017-12-14
MX388264B true MX388264B (es) 2025-03-19

Family

ID=56614902

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017010370A MX388264B (es) 2015-02-10 2016-02-09 Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
MX2021004294A MX2021004294A (es) 2015-02-10 2017-08-10 Suministro mejorado de particulas virales al cuerpo estriado y al cortex.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004294A MX2021004294A (es) 2015-02-10 2017-08-10 Suministro mejorado de particulas virales al cuerpo estriado y al cortex.

Country Status (27)

Country Link
US (2) US20190111157A1 (es)
EP (3) EP3256594B1 (es)
JP (4) JP6928558B2 (es)
KR (2) KR102863734B1 (es)
CN (2) CN107530447A (es)
AU (3) AU2016219398A1 (es)
BR (1) BR112017017037A2 (es)
CA (1) CA2976082A1 (es)
CL (1) CL2017002028A1 (es)
CR (1) CR20170407A (es)
DK (1) DK3256594T3 (es)
EA (1) EA201791803A1 (es)
ES (1) ES2904504T3 (es)
HU (1) HUE057272T2 (es)
IL (4) IL313840A (es)
LT (1) LT3256594T (es)
MX (2) MX388264B (es)
NZ (1) NZ772772A (es)
PH (1) PH12017501436A1 (es)
PL (1) PL3256594T3 (es)
PT (1) PT3256594T (es)
RS (1) RS62811B1 (es)
SG (3) SG11201706445SA (es)
SI (1) SI3256594T1 (es)
TN (1) TN2017000353A1 (es)
TW (1) TWI730952B (es)
WO (1) WO2016130591A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
KR20170096998A (ko) 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2016077689A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CR20170407A (es) * 2015-02-10 2017-11-14 Genzyme Corp Mejora del suministro de partículas virales al cuerpo estriado y al córtex
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
US11020443B2 (en) 2015-04-23 2021-06-01 University Of Massachusetts Modulation of AAV vector transgene expression
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX2018003702A (es) 2015-09-24 2018-04-30 Biomarin Pharm Inc Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden.
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024448C (en) 2016-05-18 2025-09-09 Voyager Therapeutics, Inc. MODULATING POLYNUCLEOTIDES
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics Inc composições e métodos de tratamento da doença de huntington
JP2019531787A (ja) 2016-08-30 2019-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
US11338046B2 (en) 2016-09-30 2022-05-24 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
CN118813559A (zh) * 2017-03-31 2024-10-22 北京三诺佳邑生物技术有限责任公司 shRNA表达框、携带其的多核苷酸序列及其应用
CA3059891A1 (en) 2017-04-14 2018-10-18 National Taiwan University Gene therapy for aadc deficiency
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG11201909868YA (en) * 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
CA3075656A1 (en) 2017-09-29 2019-04-04 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
BR112020020836A2 (pt) 2018-04-13 2021-01-19 University Of Massachusetts Vetores de aav bicistrônicos codificando subunidades alfa e beta de hexosaminidase e usos dos mesmos
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
US12448629B2 (en) 2018-10-05 2025-10-21 University Of Massachusetts rAAV vectors for the treatment of GM1 and GM2 gangliosidosis
CA3117982A1 (en) * 2018-11-14 2020-05-22 Bhargavi KONDRAGUNTA Gene therapy for neuronal ceroid lipofuscinoses
KR20210131370A (ko) * 2019-02-22 2021-11-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
US20220307024A1 (en) * 2019-06-17 2022-09-29 Alnylam Pharmaceuticals, Inc. Delivery of oligonucleotides to the striatum
WO2021007382A1 (en) * 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
US20220275367A1 (en) * 2019-07-24 2022-09-01 Voyager Therapeutics, Inc. Compositions and methods for treating huntington's disease
US12442017B2 (en) 2020-03-02 2025-10-14 National University Corporation Gunma University Microglial selective gene expression vector
CN115335512A (zh) * 2020-03-11 2022-11-11 瑞莫特治疗公司 用于在整个中枢神经系统中传播蛋白质的方法和材料
CN116171166A (zh) * 2020-06-30 2023-05-26 塞其里斯英国有限公司 水包油乳液佐剂的冷过滤
AU2022212922A1 (en) * 2021-01-27 2023-08-17 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
US20230034817A1 (en) 2021-04-12 2023-02-02 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
WO2023108507A1 (en) * 2021-12-15 2023-06-22 National Institute Of Biological Sciences, Beijing Recombinant aav vectors and use thereof
US20250333758A1 (en) * 2021-12-15 2025-10-30 Genans Biotechnology Co., Ltd Microglia having car and use thereof
AU2023364350A1 (en) 2022-10-19 2025-06-05 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2025151454A1 (en) * 2024-01-08 2025-07-17 AskBio Inc. Method or system of infusing and/or predicting an infusate volume
WO2025227063A1 (en) 2024-04-26 2025-10-30 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US5735815A (en) 1993-07-26 1998-04-07 Sentinel Medical, Inc. Method of using fluid jet surgical cutting tool
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP1080202B1 (en) * 1998-05-27 2006-01-25 Avigen, Inc. Convection-enhanced delivery of aav vectors encoding aadc
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
WO2003004660A1 (en) 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
SG168422A1 (en) 2001-11-13 2011-02-28 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
GB2389791B (en) 2002-04-30 2006-12-13 Steven Gill Implantable drug delivery pump
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
CA2581714C (en) 2004-10-05 2017-09-12 Avigen, Inc. Stepped cannula
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
BRPI0611379A2 (pt) * 2005-05-02 2010-08-31 Genzyme Corp terapia genética para distúrbios neurometabólicos
US9089667B2 (en) 2005-08-23 2015-07-28 The Regents Of The University Of California Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
AU2007244826B2 (en) 2006-04-25 2013-04-11 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders
WO2007127839A2 (en) 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
ES2557482T3 (es) 2007-05-17 2016-01-26 Medgenesis Therapeutix Inc. Catéter de entrega mejorada por convección con un miembro de rigidización eliminable
EP2391388A1 (en) * 2009-01-29 2011-12-07 University of California-San Francisco Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders
SMT201800554T1 (it) 2009-06-16 2018-11-09 Genzyme Corp Metodi migliorati per la purificazione di vettori di aav ricombinanti
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2673286B1 (en) * 2011-02-12 2019-07-03 University of Iowa Research Foundation Therapeutic compounds
SG10202007803QA (en) 2011-02-17 2020-09-29 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
CR20170407A (es) * 2015-02-10 2017-11-14 Genzyme Corp Mejora del suministro de partículas virales al cuerpo estriado y al córtex
CN111417231A (zh) 2019-01-04 2020-07-14 青岛海尔股份有限公司 电磁波发生系统及具有该电磁波发生系统的加热装置

Also Published As

Publication number Publication date
CR20170407A (es) 2017-11-14
EA201791803A1 (ru) 2017-11-30
AU2025201381A1 (en) 2025-03-20
US12465657B2 (en) 2025-11-11
IL313840A (en) 2024-08-01
EP4219728A2 (en) 2023-08-02
SG11201706445SA (en) 2017-09-28
CL2017002028A1 (es) 2018-04-13
IL296466A (en) 2022-11-01
TW201642909A (zh) 2016-12-16
EP3256594B1 (en) 2021-10-20
KR102625784B1 (ko) 2024-01-15
EP4023758A1 (en) 2022-07-06
HK1246340A1 (zh) 2018-09-07
IL296466B2 (en) 2024-11-01
DK3256594T3 (da) 2022-01-24
JP2021178861A (ja) 2021-11-18
IL296466B1 (en) 2024-07-01
JP2018506585A (ja) 2018-03-08
LT3256594T (lt) 2022-02-10
PT3256594T (pt) 2022-01-18
US20190111157A1 (en) 2019-04-18
KR20240010539A (ko) 2024-01-23
AU2022204583A1 (en) 2022-07-21
PH12017501436A1 (en) 2018-01-15
IL253894A0 (en) 2017-10-31
TWI730952B (zh) 2021-06-21
NZ735290A (en) 2023-10-27
RS62811B1 (sr) 2022-02-28
CA2976082A1 (en) 2016-08-18
HUE057272T2 (hu) 2022-04-28
IL285060A (en) 2021-08-31
WO2016130591A3 (en) 2016-11-10
BR112017017037A2 (pt) 2018-04-10
SG10201912926VA (en) 2020-02-27
WO2016130591A2 (en) 2016-08-18
TN2017000353A1 (en) 2019-01-16
PL3256594T3 (pl) 2022-02-14
NZ772772A (en) 2024-12-20
JP6928558B2 (ja) 2021-09-01
SI3256594T1 (sl) 2022-07-29
MX2021004294A (es) 2021-06-04
MX2017010370A (es) 2017-12-14
CN107530447A (zh) 2018-01-02
ES2904504T3 (es) 2022-04-05
IL285060B2 (en) 2023-02-01
IL253894B (en) 2021-08-31
KR20170110718A (ko) 2017-10-11
KR102863734B1 (ko) 2025-09-25
EP3256594A2 (en) 2017-12-20
IL285060B (en) 2022-10-01
SG10201907399RA (en) 2019-09-27
AU2016219398A1 (en) 2017-09-28
EP4219728A3 (en) 2023-08-23
JP2025060823A (ja) 2025-04-10
CN116019934A (zh) 2023-04-28
JP2023058630A (ja) 2023-04-25
US20220395586A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
MX388264B (es) Suministro mejorado de particulas virales al cuerpo estriado y al cortex.
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
IL259595B1 (en) Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use
MX376190B (es) PARTÍCULAS DE rAAV QUE CODIFICAN miR-708 Y USOS DEL MISMO.
BR112015021884A8 (pt) vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
PL3294323T3 (pl) Wirus związany z adenowirusem do terapeutycznego dostarczania do ośrodkowego układu nerwowego
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
MX2018004755A (es) Entrega de polinucleotidos dirigidos al sistema nervioso central.
MX2023013509A (es) Composiciones farmaceuticas que comprenden raav para la terapia genica galgt2 para trastornos neuromusculares y uso de las mismas.
CL2022000292A1 (es) Partículas virales para uso en el tratamiento de sinucleinopatías tales como enfermedad de parkinson mediante terapia genética
MA40818A1 (fr) Administration améliorée de particules virales au striatum et au cortex
HK1261543A1 (en) Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use